Thorinane, INN enoxaparin sodium

Inhixa, INN enoxaparin sodium

Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy.

OBJECTIVE We sought to evaluate the pharmacokinetics of subcutaneously administered enoxaparin sodium during and after pregnancy. STUDY DESIGN Daily subcutaneous injections of enoxaparin sodium (40 mg) were administered to 13 pregnant women. On 3 separate occasions, once early in pregnancy (12-15 weeks), once late in pregnancy (30-33 weeks), and once in the nonpregnant state (6-8 weeks post p...

Incidence and Extent of Bruising After Subcutaneous Injection of Enoxaparin Sodium in Patients Hospitalized at Coronary Care Units

Introduction: Bruising or ecchymosis after subcutaneous injection of enoxaparin sodium can cause anxiety and discomfort in the patient. Therefore, nurses should know the factors associated with the incidence and extent of this complication. Objective: This study aims to investigate incidence and extent of bruising after subcutaneous injection of enoxaparin sodium and its related factors in pat...

The introduction of biosimilars of low molecular weight heparins in Europe: a critical review and reappraisal endorsed by the Italian Society for Haemostasis and Thrombosis (SISET) and the Italian Society for Angiology and Vascular Medicine (SIAPAV)

Recently, the European Medicines Agency (EMA) authorized the introduction and marketing of Thorinane® and Inhixa®, biosimilars of the Low Molecular Weight Heparin (LMWH) enoxaparin. The authorization path is considerably different from the guidelines published by the EMA in 2009, as well as from the recommendations from the International Society on Thrombosis and Haemostasis published in 2013. ...

Development of enoxaparin sodium polymeric microparticles for colon-specific delivery

BACKGROUND AND AIMS Recent studies have shown that low molecular weight heparins are effective in the treatment of inflammatory bowel disease. Therefore, there is considerable interest in the development of an oral colonic delivery pharmaceutical system allowing targeted release of heparin in the inflamed tissue. The objective of this study was to prepare microparticles for the oral administrat...